



CITTA' DI  
REGGIO CALABRIA



Associazione Italiana  
Radioterapia e Oncologia clinica



AZIENDA SANITARIA  
PROVINCIALE  
REGGIO CALABRIA



CALABRIA

First international  
congress of

# BIOIMMUNOTHERAPY OF CANCER

An International multidisciplinary meeting

Responsabile Scientifico:

**Dr. Pierpaolo Correale**

**12-13-14**  
**APRILE 2019**

**REGGIO CALABRIA**  
**ITALY**

Palazzo della Provincia, Sala Perri, Piazza Italia,  
89125 Reggio Calabria



# April, FRIDAY 12th, 2019

**Ore 8.30** Authority salutation

Vice-Ministro dell'economia, *Onorevole Senatore Massimo Garavaglia*

Autorità regionali

Autorità Città Metropolitana

Direzione Strategica Grande ospedale Metropolitano

Associazione Salute Donna ONLUS: *Anna Mancuso*

Associazione ARCO: *Francesco Provenzano*

**Ore 9.30 INTRODUCTION:**

*Prof. Angelo Raffaele Bianco, Prof. Luigi Pirtoli, Prof. Pierosandro Tagliaferri,*

*Dr. Pierpaolo Correale*

## GENERAL SESSION

### STANDARD CARE AND PATIENT MANAGEMENT

(Lingua ufficiale Italiano):

CHAIRMEN: *Mario Roselli and Sabino de Placido*

**Ore 9.45 / Ettore Jorio**

Interrelazione ospedale territorio

**Ore 10.00 / Fiorella Guadagni**

Dalle Banche dati alla pratica clinica

**Ore 10.15 / Claudio Verusio**

Il passo dalla diagnosi alla presa in carico della "persona" paziente

**Ore 10.30 / Pierpaolo Correale**

Real World Evidence in Oncologia

**Ore 10.45 / Salvatore Palazzo**

Sostenibilità dei nuovi trattamenti, reperimento e razionalizzazione delle risorse

**Ore 11.00 / Giovanna Chiappetta**

Il consenso informato: tutela del paziente o difesa del medico

**Ore 11.15 / Antonio Giordano**

Le collaborazioni internazionali; formazione e leadership

**Ore 11.30 / Stefano Magrini**

Riorganizzazione della rete radioterapica regionale

**Ore 11.45 / Giovanna Malara**

Un modello di integrazione multi-disciplinare complessa nella diagnosi e cura del melanoma maligno; target therapy e immunocheckpoint

**Ore 12.00 / Rocco Giannicola**

Organizzazione, attrezzatura e necessità irrinunciabili per la creazione di una lung unit efficiente

**Ore 12.15 / Antonio Santo**

Una forza nazionale integrata contro il carcinoma polmonare

**Ore 12.45 / Guido Francini**

L'Oncologia nel paziente anziano

**Ore 13.00 / Maria Angela Polifrone**

La valutazione psiconcologica del paziente con carcinoma polmonare

**LUNCH**

---

## Bio-immunotherapy congress

(Lingua ufficiale Inglese):

WORK OPENING: *Luigi Pirtoli, Pierosandro Tagliaferri, Pierpaolo Correale*

### I SESSION

#### ADVANCEMENT FOR GENITOURINARY MALIGNANCIES

CHAIRMEN: *A Madan Ravi, Guido Francini*

**Ore 15.00 / Francesco Grillone**

Hormonal therapy evolution in prostate cancer

**Ore 15.15 / Edoardo Francini**

Role of chemotherapy in prostate cancer

**Ore 15.30 / Paolo Tini**

Salvage radiotherapy for prostate cancer; potential predictive immunological parameters of response

**Ore 15.45 / Camillo Porta**

Kidney Cancer molecular definition, inheritance and treatment implications

**Ore 16.00 / Giacomo Carteni**

TKI, mTOR inhibitors and anti-angiogenic mAbs in kidney cancer

**Ore 16.15 / Rita Agostino**

Kidney cancer a long lasting model for cancer immunotherapy: from the interleukin 2 to the immune-check point inhibitors

**Ore 16.30 / Antonino Mafodda**

Chemotherapy or immune-check point blockade in the savage treatment of metastatic urological malignancies

---

## **II Active specific Immunotherapy and immune-checkpoint inhibitors in Malignant melanoma, and Head and Neck Carcinoma (HNC)**

CHAIRMEN: *Stefano Magrini*

**Ore 17.00 / Grazia Cusi**

Viral infections and HNC: Risks and perspectives

**Ore 17.15 / Marta Maddalo**

Combined treatments for locally advanced head and neck cancer: the changing role of cetuximab and the new research avenues

**Ore 17.30 / Michele Del Vecchio**

Development of Target therapy in the treatment of malignant melanoma

**Ore 17.45 / Paola Queirolo**

Immuno-check point inhibitors in the treatment of malignant melanoma: the state of art

**Ore 18.00 / Paolo Pedrazzoli**

Vaccine and adoptive therapy in HNC

**Ore 18.15 / Rita Chiari**

New targets for small cell lung cancer

**Ore 18.30 / Carmen Tebala**

Radiological evaluation of Head and neck cancer and malignant melanoma patients receiving Immunological treatments

## **Conclusions of the day**

**Ore 20.30 DINNER**

# April, SATURDAY 13th, 2019

## III Immuno-oncological development and controversies (II)

CHAIRMEN: *Jay Berzofsky*

**Ore 8.30 / M. Sitkovsky**

Critical role of hypoxia and cancer associated inflammation

**Ore 8.45 / Robert M Hoffman**

Animal models and immunolo-oncological research

**Ore 9.00 / Jack Greiner**

Basic principles of immunotherapy, cancer vaccines, co-accessory molecules

**Ore 9.15 / Jay Berzofsky**

Active specific immunotherapy Translation from mice to human clinical trials

**Ore 9.30 / A. Madan Ravi**

Immuno-oncological treatments for prostate carcinoma future directions

**Ore 9.45 / Massimo Di Maio**

History and clinical development of therapeutic immune-checkpoint blockades; future challenges

**Ore 10.00 / Vincenzo Desiderio**

Endoplasmic stress as a new target for anticancer therapies and immunological treatments

**Ore 10.15 / Fabio Malavasi**

Interplay between Fc domain of therapeutic antibodies and specific receptors on different effector populations

**Ore 10.30 / Claudio Tripodo**

Mechanism of failure of immune-checkpoints: effector failure or tumor resistance

**Ore 10.45 / Kkosmatopoulos**

There still a role for cancer vaccine?

**Ore 11.00 / Bruno Cadilha**

Chemokine receptors enable adoptive T cell therapy homing into solid tumors

**Ore 11.15 / Sonia Quarantino**

Immunomodulation in cancer beyond PD-1 and PD-L1

**Ore 11.30 / Takuia Tsunoda**

The new generations of immunecheckpoint inhibitors

**Ore 11.45 / Pierpaolo Correale**

PD-1 blockade: Antigen cascade, Autoimmunity and Major Histocompatibility Complex -

**COFFEE BREAK**

---

## **IV Immuno-oncological development and controversies (neoantigens, immunoprimering and monoclonal antibodies)**

CHAIRMEN: *Kwong Yok Tsang and Fabio Malavasi*

**Ore 12.00 / Pierfrancesco Tassone**

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Human Malignancies

**Ore 12.15 / Kwong Yok Tsang**

Mechanisms of action of a neoantigen-targeting antibody NEO-201

**Ore 12.30 / Alfredo Colombo**

ADCC : from bench to bedside

**Ore 12.45 / Massimo Fantini**

An IL-15 superagonist, ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) elicited by the novel monoclonal antibody NEO-201 against human carcinoma cells

**Ore 13.00 / Christina Messineo Annunziata**

Immunotherapy in the treatment of gynecological malignancies

**Ore 13.15 / Caterina Alati**

New moAbs in the treatment of acute leukemia

**Ore 13.30 / Phil Arlen**

New antibodies in the treatment of bilio-pancreatic cancer

**Ore 13.45 LUNCH**

---

## **V Lung Cancer**

CHAIRMEN: *Piero Paladini, Baldo Mondello*

**Ore 14.30 / Luca Luzzi**

Role of surgery and combined approach: neoadjuvant chemoradiotherapy and radio-immunotherapy

**Ore 15.00 / Marta Castiglia**

Liquid biopsy and precision medicine

**Ore 15.15 / Nadia Pasinetti**

Target therapy on drivers mutations

**Ore 15.30 / Roberto Bianco**

Targeting EGFR pathway as treatment of non small cell lung cancer

**Ore 16.00 / Vito Barbieri**

The Advent of immunotherapy from now to the future

**Ore 16.15 / Rocco Giannicola**

Care and monitoring of NSCLC patient in treatment with immune-checkpoint blockade:  
iRAEs Pain, Emesis, Infection, and quality of life

**Ore 16.30 / Pierpaolo Pastina**

Radiotherapy, new perspective and immunobiological effects

**Ore 16.45 / Valerio Nardone**

Immune-checkpoint blockade Response evaluation by Digital analysis

**Ore 17.00 / Luca Volterrani**

Radiological and clinical evaluation of Lung Cancer patients treated with  
immunotherapy or target therapy

---

## **VI Immuno-oncological development and controversies on adoptive therapy and micro RNA**

CHAIRMEN: *Massimo Martino and Bruno Martino*

**Ore 17.15 / Massimo Martino**

Donor lymphocyte infusions in AML and MDS?

**Ore 17.30 / Giulia Pucci**

Processing CSE toward Jacie accreditation

**Ore 17.45 / Patrizia Comoli**

T cell therapy for viral infections

**Ore 18.00 / Ciro Botta**

Immunobiological characterization of Tumor infiltrating lymphocytes  
derived from multiple myeloma patients

**Ore 18.15 / Marco Rossi**

Car-T based immunotherapy and adoptive therapy

**Ore 18.30 / Michele Caraglia**

Micro-RNAs and long non coding RNAs loops in human cancers: a new deal in anti-cancer treatment and immunotherapy

## **Take the message round table**

DISCUSSION LEADERS: *Chairmen: Massimo Martino and Bruno Martino*

April,SUNDAY 14th, 2019

## **VII Advancement in Gastro-enteric malignancies**

CHAIRMEN: *Antonio Russo, Gianfranco Filippelli*

**Ore 9.00 / Candida Mastroianni**

Anti-angiogenic treatments in gastro-enteric malignancies

**Ore 9.15 / Martinelli Erika**

**Ore 9.30 / Pierpaolo Pastina**

Effects of inflammatory status and k-ras mutation on patients response to the thymidylate synthase poly-epitope peptide vaccine

**Ore 9.45 / Teresa Troiani**

Immune-check point blockade and EGFR inhibition in advanced colorectal cancer; present and future directions

**Ore 10.00 / Piersandro Tagliaferri**

Chemo-immunotherapy of Colorectal cancer; fifteen years of GOLFIC experience

---

## **VIII session – Advancement in gynecological malignancies and breast cancer**

CHAIRMEN: *Sandro Pignata and Serafino Conforti*

**Ore 10.15 / Stefano Palomba**

Surgery and combined therapeutic approaches to ovary and endometrial cancer

**Ore 10.30 / Sandro Pignata**

From the anti-blastic drugs to PARP inhibitor

**Ore 10.45 / Pietro Del Medico**

Chemo-immunological treatments of gynaecological malignancies

**Ore 11.00 / Paolo Vigneri**

New pathways for breast cancer treatment; from bench to the bedside and vice-versa

**Ore 11.15 / Salvatore Vaccarella**

Il ruolo della medicina di precisione nella pratica oncologica

**Ore 11.30 / Carmelo Tuscano**

Radiotherapy and Cervical carcinoma, role of integrated treatments

**Ore 11.45 / Roberto Maisano**

The unstoppable advent of cycline inhibitors

**Ore 12.00 / Francesca Di Rella**

NPDL-1 blockade in the treatment of triple negative breast cancer

**Ore 12.15 / Michele Caruso**

The new directions of cycline inhibitors

**Congress conclusions and salutations:**

Michail Sitkovsky, Piersandro Tagliaferri, Pierpaolo Correale

First international congress of  
**Bioimmunotherapy of Cancer**  
An International multidisciplinary meeting

**12-13-14 APRILE 2019 | REGGIO CALABRIA, ITALY**

Responsabile Scientifico: **Dr. Pierpaolo Correale**

Il convegno è stato accreditato su Agenas, ha ottenuto i seguenti crediti formativi:

**12 Aprile** 2019 id 5090 - 253291 crediti assegnati N. **4.9**

**13 Aprile** 2019 id 5090- 253313 crediti assegnati N. **6.3**

**14 Aprile** 2019 id 5090- 253324 crediti assegnati N. **2.1**

Il convegno e' rivolto a N. **150** partecipanti PROVENIENZA REGIONALE

PROFESSIONE: MEDICO CHIRURGO

Discipline in: Allergologia ed immunologia clinica; anatomia patologica; chirurgia generale; chirurgia toracica; dermatologia e venereologia; ematologia; genetica medica; medicina generale (*medici di famiglia*); medicina interna; oncologia; radioterapia; urologia.

PROFESSIONE: INFERMIERE

Discipline in: Infermiere

PROFESSIONE: BIOLOGO

discipline in: Biologo

PROFESSIONE: FARMACISTA

discipline in: Farmacia ospedaliera; farmacia territoriale;

Tipologia evento: CORSO DI AGGIORNAMENTO

Obiettivi dell'Evento: LINEE GUIDA - PROTOCOLLI - PROCEDURE

**CORSO GRATUITO**

L'iscrizione è gratuita e può essere effettuata tramite e-mail all'indirizzo: **xeniaeventi@gmail.com**, allegando i dati anagrafici o telefonare al numero **0984.444890**

PROVIDER E SEGRETERIA ORGANIZZATIVA



**XENIA**  
WE DEVELOP YOUR IDEAS

Xenia S.a.s. di Francesca Mazza & C.  
Via G. Verdi, 144 - 87036 Rende CS  
Tel. **0984 444 890** - Cell. **3441872101**

E-mail: **xeniaeventi@gmail.com** | Id Provider **5090**

Patrocinio concesso da



L' Iniziativa è stata realizzata grazie al supporto incondizionato di:



Bristol-Myers Squibb

